Advertisement

Drug Safety

, Volume 30, Issue 11, pp 991–994 | Cite as

Use of Enoxaparin in Patients with Chronic Kidney Disease

Safety Considerations
Commentary

Notes

Acknowledgements

The authors have no conflicts of interest that are directly relevant to the content of this commentary. No sources of funding were used to assist in the preparation of this commentary.

References

  1. 1.
    Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30(5): 579–89PubMedCrossRefGoogle Scholar
  2. 2.
    United States Renal Data Systems (USRDS). 2006 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Chapter 6: Morbidity and mortality. Am J Kidney Dis 2007; 49 (1 Suppl.): S130–46994Google Scholar
  3. 3.
    Antman EM, McCabe CH, Gurfinkle EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100(15): 1593–601PubMedCrossRefGoogle Scholar
  4. 4.
    Cohen M, Demers C, Gurfinkle EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998; 82(5B): 19L–24LPubMedCrossRefGoogle Scholar
  5. 5.
    Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44: 465–97PubMedCrossRefGoogle Scholar
  6. 6.
    Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998; 56: 259–72PubMedCrossRefGoogle Scholar
  7. 7.
    Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586–90PubMedGoogle Scholar
  8. 8.
    Lovenox® (enoxaparin sodium) [package insert]. Bridgewater (NJ): Sanofi-Aventis Pharmaceuticals, 2007 JunGoogle Scholar
  9. 9.
    Brophy DF, Carr ME, Martin EJ, et al. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamics in patients receiving dialysis therapies. J Clin Pharmacol 2006; 465: 887–94CrossRefGoogle Scholar
  10. 10.
    Brophy DF, Martin EJ, Gehr TWB, et al. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006; 4: 372–6PubMedCrossRefGoogle Scholar
  11. 11.
    Gheno G, Cinetto L, Savarino C, et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003; 59: 373–7PubMedCrossRefGoogle Scholar
  12. 12.
    Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673–84PubMedGoogle Scholar
  13. 13.
    Spinier SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33–41CrossRefGoogle Scholar
  14. 14.
    Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856–63PubMedCrossRefGoogle Scholar
  15. 15.
    Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41: 8–14PubMedCrossRefGoogle Scholar
  16. 16.
    Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81–2PubMedCrossRefGoogle Scholar
  17. 17.
    Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542–52PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Division of PharmacyVirginia Commonwealth University/Medical College of Virginia CampusRichmondUSA
  2. 2.Division of NephrologyVirginia Commonwealth University/Medical College of Virginia CampusRichmondUSA
  3. 3.Section of Clinical Pharmacology and HypertensionVirginia Commonwealth University/Medical College of Virginia CampusRichmondUSA

Personalised recommendations